Hybrisan
MedTech company based in South Wales developing wound-care interventions to address bioburden and biofilm in chronic wounds. Operates multidisciplinary R&D and manufacturing-capable laboratories (microbiology, nanofibre/electrospinning, quality control) and is developing an irrigation solution for acute and chronic wounds while pursuing regulatory approvals. Engages in external collaborations and grant-funded partnerships to support R&D and product development.
Industries
Nr. of Employees
small (1-50)
Products
Wound irrigation solution (wound cleansing and moistening)
Irrigation solution intended for cleansing and moistening acute and chronic wounds; designed to mechanically remove slough/necrotic material and disrupt multispecies biofilms to support healing.
WoundSan
Multi-platform wound care technology specifically developed to address issues caused by biofilm, wound infection, and stagnant treatment technologies with low cytotoxicity and high biofilm disruption efficacy.
Wound irrigation solution (wound cleansing and moistening)
Irrigation solution intended for cleansing and moistening acute and chronic wounds; designed to mechanically remove slough/necrotic material and disrupt multispecies biofilms to support healing.
WoundSan
Multi-platform wound care technology specifically developed to address issues caused by biofilm, wound infection, and stagnant treatment technologies with low cytotoxicity and high biofilm disruption efficacy.
Expertise Areas
- Wound-care product development
- Antimicrobial and antibiofilm research
- Nanofibre development and scale-up
- Microbiology and in vitro biofilm testing
Key Technologies
- Electrospinning (nanofibre production)
- Free-surface electrospinning production line
- Scanning electron microscopy (SEM)
- In vitro multispecies biofilm assays